Compare Ono Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
The company has declared Positive results for the last 3 consecutive quarters
- NET PROFIT(HY) At JPY 24,969 MM has Grown at 126.09%
- OPERATING CASH FLOW(Y) Highest at JPY 134,501 MM
- RAW MATERIAL COST(Y) Fallen by -6.19% (YoY)
2
With ROE of 8.22%, it has a very attractive valuation with a 1.32 Price to Book Value
3
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,199,356 Million (Large Cap)
16.00
NA
0.00%
-0.15
8.22%
1.41
Revenue and Profits:
Net Sales:
116,160 Million
(Quarterly Results - Jun 2026)
Net Profit:
24,163 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.85%
0%
0.85%
6 Months
-4.19%
0%
-4.19%
1 Year
39.86%
0%
39.86%
2 Years
12.69%
0%
12.69%
3 Years
-12.61%
0%
-12.61%
4 Years
-28.73%
0%
-28.73%
5 Years
-3.66%
0%
-3.66%
Ono Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.77%
EBIT Growth (5y)
2.33%
EBIT to Interest (avg)
92.07
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.55
Tax Ratio
24.55%
Dividend Payout Ratio
53.88%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
19.84%
ROE (avg)
12.49%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.32
EV to EBIT
9.69
EV to EBITDA
7.10
EV to Capital Employed
1.38
EV to Sales
1.94
PEG Ratio
0.41
Dividend Yield
NA
ROCE (Latest)
14.24%
ROE (Latest)
8.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
116,160.00
127,536.00
-8.92%
Operating Profit (PBDIT) excl Other Income
40,160.00
32,423.00
23.86%
Interest
783.00
773.00
1.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
24,163.00
17,631.00
37.05%
Operating Profit Margin (Excl OI)
268.40%
181.80%
8.66%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -8.92% vs 8.38% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 37.05% vs -29.01% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
515,785.00
486,871.00
5.94%
Operating Profit (PBDIT) excl Other Income
141,087.00
90,278.00
56.28%
Interest
2,163.00
1,635.00
32.29%
Exceptional Items
-1,656.00
-1,645.00
-0.67%
Consolidate Net Profit
69,911.00
50,166.00
39.36%
Operating Profit Margin (Excl OI)
200.30%
130.20%
7.01%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 5.94% vs -3.14% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 39.36% vs -60.82% in Mar 2025
About Ono Pharmaceutical Co., Ltd. 
Ono Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






